ArticleJournal of inflammation research2025
Elevated Serum Podoplanin Levels Correlate with Disease Severity and Inflammation in Ulcerative Colitis: A Cross-Sectional Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Podoplanin is a transmembrane glycoprotein that is primarily expressed in lymphatic endothelial cells, fibroblasts, and certain epithelial cells. Although it has been implicated in various physiological and pathological processes, its role in ulcerative colitis (UC) remains unclear. This study aimed to investigate the association between serum podoplanin levels and disease severity in patients with UC, and its potential involvement in coagulation and inflammation in patients with UC. Methods: This cross-sectional study compared serum podoplanin levels in patients with remission-UC (n = 115), active-UC (n = 94), and healthy controls (n = 150). Active-UC patients were further classified as mild (n = 37), moderate (n = 31), or severe (n = 26) based on their Mayo scores. Clinical, inflammatory, and coagulation markers were measured and analyzed using one-way ANOVA, ROC analysis, and Pearson's correlation. Podoplanin expression in human tissues was examined using the BioGPS database (https://biogps.org/). Results: Serum podoplanin levels were significantly elevated in patients with UC (n=209) compared to healthy controls (n=150), with higher levels observed in patients with moderate (n=31) and severe (n=26) disease than in those with mild UC (n=37). Correlation analysis revealed that serum podoplanin levels were positively associated with coagulation markers-platelet count (r=0.247, p<0.001), erythrocyte sedimentation rate (ESR; r=0.695, p<0.001), D-dimer (r=0.765, p<0.001), and fibrinogen (r=0.490, p<0.001) as well as inflammatory markers, including C-reactive protein (CRP; r=0.767, p<0.001), interleukin-1beta (IL-1β; r=0.744, p<0.001), interleukin-6 (IL-6; r=0.786, p<0.001), interleukin-17A (IL-17A; r=0.788, p<0.001), tumor necrosis factor-α (TNF-α; r=0.784, p<0.001), and Mayo score (r=0.912, p<0.001). Conclusion: Elevated serum podoplanin levels are closely associated with disease activity, inflammation, and hypercoagulability in patients with UC, suggesting that it may serve as a reliable biomarker for monitoring disease severity and guiding clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.